Functional Delivery of siRNA in Mice Using Dendriworms

• Main Authors: Agrawal, Amit (Contributor), Min, Dal-Hee (Contributor), Singh, Neetu (Contributor), Zhu, Haihao (Author), Birjiniuk, Alona (Contributor), Harris, Todd J. (Contributor), Xing, Deyin (Contributor), Woolfenden, Stephen D. (Contributor), Sharp, Phillip A. (Contributor), Charest, Alain (Contributor), von Maltzhan, Geoffrey (Author), Bhatia, Sangeeta N (Author)
• Other Authors: Whitaker College of Health Sciences and Technology (Contributor), Harvard University- (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor), Bhatia, Sangeeta N. (Contributor), Von Maltzahn, Geoffrey (Contributor)
• Format: Article
• Language: English
• Published: American Chemical Society, 2011-08-23T15:36:31Z.
• Subjects: Article
• Online Access: Get fulltext

Small interfering RNAs (siRNAs) mediate cleavage of specific, complementary mRNA sequences and thus regulate gene expression. Not surprisingly, their use for treatment of diseases that are rooted in aberrant gene expression, such as cancer, has become a paradigm that has gained wide interest. Here, we report the development of dendrimer-conjugated magnetofluorescent nanoworms that we call "dendriworms" as a modular platform for siRNA delivery in vivo. This platform maximizes endosomal escape to robustly produce protein target knockdown in vivo, and is tolerated well in mouse brain. We demonstrate that siRNA-carrying dendriworms can be readily internalized by cells and enable endosomal escape across a wide range of loading doses, whereas dendrimers or nanoworms alone are inefficient. Further, we show that dendriworms carrying siRNA against the epidermal growth factor receptor (EGFR) reduce protein levels of EGFR in human glioblastoma cells by 70−80%, 2.5-fold more efficiently than commercial cationic lipids. Dendriworms were well-tolerated after 7-days of convection-enhanced delivery to the mouse brain and in an EGFR-driven transgenic model of glioblastoma, anti- EGFR dendriworms led to specific and significant suppression of EGFR expression. Collectively, these data establish dendriworms as a multimodal platform that enables fluorescent tracking of siRNA delivery in vivo, cellular entry, endosomal escape, and knockdown of target proteins.
David H. Koch Institute for Integrative Cancer Research at MIT (Cancer Research Fund)
MIT-Harvard Center for Cancer Nanotechnology Excellence (Fellowship)
National Institutes of Health (U.S.) (NIH BRP CA124427and)
National Institutes of Health (U.S.) (NIH CA119349)
Cam Neely Foundation
Marie D. and Pierre Casimir-Lambert Fund